Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 1, 2010, Pages 308-313

  Roymans, Dirk ^a   De Bondt, Hendrik L ^a   Arnoult, Eric ^b   Geluykens, Peggy ^a   Gevers, Tom ^a   Van Ginderen, Marcia ^a   Verheyen, Nick ^a   Kim, Hidong ^c   Willebrords, Rudy ^d   Bonfanti, Jean François ^b   Bruinzeel, Wouter ^d   Cummings, Maxwell D ^a   Van Vlijmen, Herman ^a   Andries, Koen ^d  

^a TIBOTEC BVBA   (Belgium)

^b Campus de Maigremont   (France)

^c DeCODE Chemistry & Biostructures   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Cocrystal structure; Respiratory syncytial virus; TMC353121; Viral fusion

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; TMC 353121; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG CONFORMATION; DRUG STABILITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL FUSION; CRYSTALLOGRAPHY, X-RAY; HELA CELLS; HUMANS; MEMBRANE FUSION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, SECONDARY; PYRIDINES; REPETITIVE SEQUENCES, AMINO ACID; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL FUSION PROTEINS;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 76249116900     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910108106     Document Type: Article

References (52)

1. Colman PM, Lawrence MC (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4:309-319.
2. Kielian M, Rey FA (2006) Virus membrane-fusion proteins: More than one way to make a hairpin. Nat Rev Microbiol 4:67-76.
3. Lamb RA, Jardetzky TS (2007) Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol 17:427-436.
4. Kadlec J, Loureiro S, Abrescia NG, Stuart DI, Jones IM (2008) The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat Struct Mol Biol 15:1024-1030.
5. Yin H-S, Paterson RG, Wen X, Lamb RA, Jardetzky TS (2005) Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci USA 102: 9288-9293.
6. Yin H-S, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439: 38-44.
7. Melikyan GB, et al. (2000) Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151: 413-423.
8. Russell CJ, Jardetzky TS, Lamb RA (2001) Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 20:4024-4034.
9. Chan DC, Chutkowski CT, Kim PS (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95: 15613-15617.
10. Zhao X, Singh M, Malashkevich VN, Kim PS (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 97: 14172-14177.
11. Bullough PA, Hughson FM, Skehel JJ, Wiley DC (1994) Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43.
12. Malashkevich VN, Singh M, Kim PS (2001) The trimer-of-hairpins motif in membrane fusion: Visna virus. Proc Natl Acad Sci USA 98:8502-8506.
13. Supekar VM, et al. (2004) Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci USA 101: 17958-17963.
14. Weissenhorn W, Carfí A, Lee KH, Skehel JJ, Wiley DC (1998) Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2:605-616.
15. Kilby JM, et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302-1307.
16. Lambert DM, et al. (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 93:2186-2191.
17. Miller SA, Tollefson S, Crowe JE Jr, Williams JV, Wright DW (2007) Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. J Virol 81: 141-149.
18. Bossart KN, et al. (2005) Inhibition of Henipavirus fusion and infection by heptadderived peptides of the Nipah virus fusion glycoprotein. Virol J 2:57.
19. Rapaport D, Ovadia M, Shai Y (1995) A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J 14:5524-5531.
20. Bosch BJ, et al. (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA 101:8455-8460.
21. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
22. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS (2007) Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA 104:16828-16833.
23. Debnath AK (2006) Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins. Curr Opin Investig Drugs 7:118-127.
24. Andries K, et al. (2003) Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 60:209-219.
25. Bonfanti J-F, et al. (2007) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: Improving the pharmacokinetic profile using the structureproperty relationship. J Med Chem 50:4572-4584.
26. Bonfanti J-F, et al. (2008) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 51:875-896.
27. Cianci C, et al. (2004) Targeting a binding pocket within the trimer-of-hairpins: Smallmolecule inhibition of viral fusion. Proc Natl Acad Sci USA 101:15046-15051.
28. Douglas JL, et al. (2005) Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similarmechanisms. Antimicrob Agents Chemother 49:2460-2466.
29. Ernst JT, et al. (2002) Design of a protein surface antagonist based on alpha-helixmimicry: Inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl 41:278-281.
30. Jiang S, Debnath AK (2000) A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem Biophys Res Commun 270:153-157.
31. Jiang S, et al. (2004) N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48: 4349-4359.
32. Liu S, et al. (2005) Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723:270-281.
33. Ferrer M, et al. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6:953-960.
34. Zhou G, et al. (2000) The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg Med Chem 8:2219-2227.
35. Plemper RK, et al. (2005) Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother 49:3755-3761.
36. Plemper RK, et al. (2004) A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci USA 101:5628-5633.
37. York J, Dai D, Amberg SM, Nunberg JH (2008) pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol 82: 10932-10939.
38. Bodian DL, et al. (1993) Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32: 2967-2978.
39. Qi Z, et al. (2008) Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem 283:30376-30384.
40. Gustchina E, Bewley CA, Clore GM (2008) Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J Virol 82:10032-10041.
41. Bond S, et al. (2005) Polycyclic agents for the treatment of respiratory syncytial virus infections. WO2005061513 A1.
42. Cianci C, et al. (2004) Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 48:413-422.
43. Dischino DD, et al. (2003) Development of a photoaffinity label for respiratory syncytial virus inhibitors. J Labelled Comp Radiopharm 46:1105-1116.
44. Eckert DM, Malashkevich VN, Kim PS (1998) Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284:859-865.
45. Doyle J, et al. (2006) Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol 80:1524-1536.
46. Russell RJ, et al. (2008) Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 105:17736-17741.
47. Prussia AJ, Plemper RK, Snyder JP (2008) Measles virus entry inhibitors: A structural proposal for mechanism of action and the development of resistance. Biochemistry 47:13573-13583.
48. Yu K-L, et al. (2007) Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. Bioorg Med Chem Lett 17:895-901.
49. Hallak LK, Spillmann D, Collins PL, Peeples ME (2000) Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:10508-10513.
50. Mossessova E, Lima CD (2000) Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol Cell 5:865-876.
51. Read RJ (1986) Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr A 42:140-149.
52. Pinheiro JC, Bates DM (2000) Mixed-Effects Models in S and S-PLUS (Springer, New York), pp 528.